Rosetta Genomics Ltd (ROSG)

1.36
NASDAQ : Health Care
Prev Close 1.43
Day Low/High 1.34 / 1.41
52 Wk Low/High 1.25 / 11.46
Avg Volume 113.50K
Exchange NASDAQ
Shares Outstanding 2.64M
Market Cap 3.77M
EPS -9.30
P/E Ratio 0.15
Div & Yield N.A. (N.A)

Latest News

Rosetta Genomics Closes Second Tranche Of Previously Announced Private Placement Of Convertible Debentures

Rosetta Genomics Ltd. (NASDAQ:ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces the closing of the second tranche of the...

Rosetta Genomics Reports Preliminary RosettaGX Reveal™ Financial Results For The 2016 Fourth Quarter And Year

Rosetta Genomics Ltd. (NASDAQ:ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces preliminary financial results and unit...

Rosetta Genomics Announces Key U.S. Patent Allowances For Two RosettaGx RevealTM MicroRNAs

Rosetta Genomics Ltd. (NASDAQ:ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces that the United States Patents and...

Rosetta Genomics Announces Pricing Of $5 Million Concurrent Registered Direct And Private Placement Offering

Rosetta Genomics Announces Pricing Of $5 Million Concurrent Registered Direct And Private Placement Offering

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, today announced it has entered into definitive agreements with one prominent...

Rosetta Genomics Enters Research Collaboration Using MicroRNA Biomarkers To Predict Response To Leading Immuno-Oncology Drug Nivolumab In Lung Cancer Patients

Rosetta Genomics Enters Research Collaboration Using MicroRNA Biomarkers To Predict Response To Leading Immuno-Oncology Drug Nivolumab In Lung Cancer Patients

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company has entered into a research agreement with Sheba Medical Center at Tel...

Clinical Validation Study For RosettaGX Reveal Published In The Journal Of Clinical Pathology

Clinical Validation Study For RosettaGX Reveal Published In The Journal Of Clinical Pathology

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that a clinical validation study in support of RosettaGX Reveal™ (Reveal), the...

RosettaGX Reveal™ Analytical Validation Study Featured On The Cover Of The October Issue Of Cancer Cytopathology

RosettaGX Reveal™ Analytical Validation Study Featured On The Cover Of The October Issue Of Cancer Cytopathology

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that an article highlighting the analytical validation data from a study of the Company's...

Rosetta Genomics Appoints Mark R. Willig As Chief Commercial Officer

Rosetta Genomics Appoints Mark R. Willig As Chief Commercial Officer

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the appointment of Mark R.

Rosetta Genomics Fortifies Intellectual Property Portfolio With Two New Patent Allowances For Its Novel MicroRNA Platform Technology

Rosetta Genomics Fortifies Intellectual Property Portfolio With Two New Patent Allowances For Its Novel MicroRNA Platform Technology

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company has added two new patent allowances to its intellectual property...

Rosetta Genomics Enters Distribution Agreement For RosettaGX Reveal™ In Israel With Rhenium

Rosetta Genomics Enters Distribution Agreement For RosettaGX Reveal™ In Israel With Rhenium

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company has entered into an exclusive distribution agreement with Rhenium...

Rosetta Genomics Reports 2016 Second Quarter Financial Results

Rosetta Genomics Reports 2016 Second Quarter Financial Results

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, reports financial results for the three and six months ended June 30, 2016.

Rosetta Genomics To Host 2016 Second Quarter Financial Results And Business Update Conference Call On September 26, 2016

Rosetta Genomics To Host 2016 Second Quarter Financial Results And Business Update Conference Call On September 26, 2016

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company will file its financial results for the three and six months ended...

Rosetta Genomics To Present At Upcoming September Conferences

Rosetta Genomics To Present At Upcoming September Conferences

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that Kenneth A.

Data Validating The Utility Of RosettaGX Reveal™ With Liquid-based Cytology Samples Will Be Presented At The 86th Annual Meeting Of The American Thyroid Association

Data Validating The Utility Of RosettaGX Reveal™ With Liquid-based Cytology Samples Will Be Presented At The 86th Annual Meeting Of The American Thyroid Association

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the results from an analytical validation study confirming that the Company's...

RosettaGX Reveal™ Thyroid MiRNA Classifier Now Available To Be Utilized On ThinPrep® Samples

RosettaGX Reveal™ Thyroid MiRNA Classifier Now Available To Be Utilized On ThinPrep® Samples

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the Company's first-of-its-kind microRNA classifier for indeterminate thyroid...

Rosetta Genomics Selected By A Global Pharmaceutical Company To Supply FISH Testing Services For Clinical Study In Prostate Cancer

Rosetta Genomics Selected By A Global Pharmaceutical Company To Supply FISH Testing Services For Clinical Study In Prostate Cancer

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the Company has entered into a services agreement with an unnamed global...

Rosetta Genomics Expands Molecular Diagnostics Test Menu With Launch Of OncoGxSelect™ From Admera Health

Rosetta Genomics Expands Molecular Diagnostics Test Menu With Launch Of OncoGxSelect™ From Admera Health

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the launch of OncoGxSelect™, a next generation sequencing (NGS)-based test that...

Rosetta Expands Managed Care Coverage With New Preferred Provider Agreement With Galaxy Health Network For Entire Suite Of Diagnostic Tests And Services

Rosetta Expands Managed Care Coverage With New Preferred Provider Agreement With Galaxy Health Network For Entire Suite Of Diagnostic Tests And Services

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces a new participation agreement with Preferred Provider Organization (PPO), Galaxy...

Rosetta Genomics Receives U.S. Patent Allowance For MicroRNA-based Ovarian Cancer Treatment

Rosetta Genomics Receives U.S. Patent Allowance For MicroRNA-based Ovarian Cancer Treatment

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces that the United States Patent and Trademark Office (USPTO) has issued a...

Rosetta Genomics To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Rosetta Genomics To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company will be participating at Cantor Fitzgerald's 2 nd Annual Healthcare...

Rosetta Expands Managed Care Coverage With New Preferred Provider Agreement For Entire Suite Of Diagnostic Tests And Services

Rosetta Expands Managed Care Coverage With New Preferred Provider Agreement For Entire Suite Of Diagnostic Tests And Services

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces a new participation agreement with Preferred Provider Organization (PPO), Stratose Inc.

Rosetta Genomics Receives Approval From New York State For HEME FISH-based Assays

Rosetta Genomics Receives Approval From New York State For HEME FISH-based Assays

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces receipt of conditional approval from the New York State Department of...

Rosetta Genomics Announces Publication Of Data Confirming Analytical Validity Of Its Novel Thyroid Nodule Classification Assay

Rosetta Genomics Announces Publication Of Data Confirming Analytical Validity Of Its Novel Thyroid Nodule Classification Assay

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announced that data from the analytical validation of the Company's novel, microRNA-based assay for...

Rosetta Genomics Receives Approval From New York State For Four PCR-Based Assays

Rosetta Genomics Receives Approval From New York State For Four PCR-Based Assays

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces receipt of conditional approval from the New York State Department of Health...

Rosetta Genomics Reports 2016 First Quarter Financial Results

Rosetta Genomics Reports 2016 First Quarter Financial Results

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the three months ended March 31, 2016.

Rosetta Genomics To Host 2016 First Quarter Financial Results And Business Update Conference Call On May 19, 2016

Rosetta Genomics To Host 2016 First Quarter Financial Results And Business Update Conference Call On May 19, 2016

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company will file its financial results for the three months ended March 31,...

Rosetta Genomics Reports 2015 Full Year Financial Results

Rosetta Genomics Reports 2015 Full Year Financial Results

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the 12 months ended December 31, 2015.

Rosetta Genomics To Host Business Update And 2015 Year-End Financial Results Conference Call On March 23, 2016

Rosetta Genomics To Host Business Update And 2015 Year-End Financial Results Conference Call On March 23, 2016

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that following the close of the U.